AVECRIS
Singapore
About AVECRIS
AVECRIS platform extends the capabilities of mRNA / RNA approaches. AVECRIS provides the following services: cell-type specific gene expression / Protein expression that is stable and long-lasting / Non-integrating, unlikely to elicit innate immunity / Redosable and titratable / Unprecedented ability to deliver mitochondrial gene therapy / A DNA-based backbone construct that is universal, unmodified, and has a modular coding region that allows for rapid and infinite application programming / Manufacturing that is quick, dependable, highly scalable, and low-cost.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $3.6M
- Last round: Grant (Aug 2022)
- Website: avecris.com
- Phone: [email protected]
Industries & Categories
Genetics, Life Science
Social Profiles
Canonical: https://fsome.com/organization/avecris-135064 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.